share_log

Cantor Fitzgerald Initiates Coverage On Sorrento Therapeutics With Overweight Rating, Announces Price Target of $5

Cantor Fitzgerald Initiates Coverage On Sorrento Therapeutics With Overweight Rating, Announces Price Target of $5

坎托·菲茨杰拉德以增持评级开始对索伦托疗法进行报道,宣布目标股价为5美元
Benzinga Real-time News ·  2022/11/02 09:28

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Sorrento Therapeutics (NASDAQ:SRNE) with a Overweight rating and announces Price Target of $5.

Cantor Fitzgerald分析师布兰登·福克斯对索伦托治疗公司(纳斯达克:SRNE)发起增持评级,并宣布目标价为5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发